Ask AI
ProCE Banner Activity

Updates in SCLC: Experts Address Questions on Practice-Changing Evidence From 2025 Global Congresses

Clinical Thought

In this commentary, experts address audience questions on the implications of practice-changing trials for limited- and extensive-stage small-cell lung cancer presented at global congresses in 2025. They address the integration of immunotherapy, maintenance therapy, and targeted therapy, as well as offer guidance to community healthcare professionals to optimize patient outcomes.

Released: May 27, 2026

Continue Activity View Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

This activity is supported by educational funding provided by Amgen and Boehringer Ingelheim Pharmaceuticals, Inc.

Amgen

Boehringer Ingelheim Pharmaceuticals, Inc.

Target Audience

This activity is intended for oncologists and other healthcare professionals caring for patients with small cell lung cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Summarize key efficacy and safety findings from the 2025 ASCO, ESMO, and WCLC meetings that inform first-line and maintenance treatment decisions for patients with limited-stage and extensive-stage SCLC

  • Evaluate the role of immunotherapy in the evolving management of limited-stage and extensive-stage SCLC, including new evidence supporting consolidation or maintenance strategies

  • Analyze recent data on lurbinectedin, DLL3-targeted bispecific antibodies, and antibody–drug conjugates to support optimal sequencing strategies for patients with relapsed/refractory SCLC

Disclosure

Primary Author

Charles Rudin, MD, PhD: consultant: AbbVie, Amgen, Daiichi Sankyo, Genentech, Merck, Novartis.

Mark A. Socinski, MD: consultant/advisor/speaker: AstraZeneca.